545 related articles for article (PubMed ID: 12750278)
21. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH
Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460
[TBL] [Abstract][Full Text] [Related]
22. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
[TBL] [Abstract][Full Text] [Related]
23. 4-1BB costimulation promotes human T cell adhesion to fibronectin.
Kim YJ; Mantel PL; June CH; Kim SH; Kwon BS
Cell Immunol; 1999 Feb; 192(1):13-23. PubMed ID: 10066342
[TBL] [Abstract][Full Text] [Related]
24. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role.
Aruga A; Aruga E; Tanigawa K; Bishop DK; Sondak VK; Chang AE
J Immunol; 1997 Jul; 159(2):664-73. PubMed ID: 9218581
[TBL] [Abstract][Full Text] [Related]
25. Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28- T cells.
Chu NR; DeBenedette MA; Stiernholm BJ; Barber BH; Watts TH
J Immunol; 1997 Apr; 158(7):3081-9. PubMed ID: 9120260
[TBL] [Abstract][Full Text] [Related]
26. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells.
Akiba H; Oshima H; Takeda K; Atsuta M; Nakano H; Nakajima A; Nohara C; Yagita H; Okumura K
J Immunol; 1999 Jun; 162(12):7058-66. PubMed ID: 10358148
[TBL] [Abstract][Full Text] [Related]
27. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.
Cho HR; Kwon B; Yagita H; La S; Lee EA; Kim JE; Akiba H; Kim J; Suh JH; Vinay DS; Ju SA; Kim BS; Mittler RS; Okumura K; Kwon BS
Transpl Int; 2004 Aug; 17(7):351-61. PubMed ID: 15349720
[TBL] [Abstract][Full Text] [Related]
28. Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses.
Tan JT; Ha J; Cho HR; Tucker-Burden C; Hendrix RC; Mittler RS; Pearson TC; Larsen CP
Transplantation; 2000 Jul; 70(1):175-83. PubMed ID: 10919597
[TBL] [Abstract][Full Text] [Related]
29. Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy.
Sica G; Chen L
Arch Immunol Ther Exp (Warsz); 1999; 47(5):275-9. PubMed ID: 10604232
[TBL] [Abstract][Full Text] [Related]
30. Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion.
Sussman JJ; Parihar R; Winstead K; Finkelman FD
Cancer Res; 2004 Dec; 64(24):9124-30. PubMed ID: 15604282
[TBL] [Abstract][Full Text] [Related]
31. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
32. Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
Cheuk AT; Mufti GJ; Guinn BA
Cancer Gene Ther; 2004 Mar; 11(3):215-26. PubMed ID: 14671675
[TBL] [Abstract][Full Text] [Related]
33. Costimulation of human CD28- T cells by 4-1BB ligand.
Bukczynski J; Wen T; Watts TH
Eur J Immunol; 2003 Feb; 33(2):446-54. PubMed ID: 12645943
[TBL] [Abstract][Full Text] [Related]
34. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
35. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
Aruga A; Aruga E; Cameron MJ; Chang AE
J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
[TBL] [Abstract][Full Text] [Related]
36. Induction of costimulation of human CD4 T cells by tumor necrosis factor-related apoptosis-inducing ligand: possible role in T cell activation in systemic lupus erythematosus.
Tsai HF; Lai JJ; Chou AH; Wang TF; Wu CS; Hsu PN
Arthritis Rheum; 2004 Feb; 50(2):629-39. PubMed ID: 14872508
[TBL] [Abstract][Full Text] [Related]
37. Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy.
Wilcox RA; Flies DB; Wang H; Tamada K; Johnson AJ; Pease LR; Rodriguez M; Guo Y; Chen L
Cancer Res; 2002 Aug; 62(15):4413-8. PubMed ID: 12154048
[TBL] [Abstract][Full Text] [Related]
38. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.
Melero I; Johnston JV; Shufford WW; Mittler RS; Chen L
Cell Immunol; 1998 Dec; 190(2):167-72. PubMed ID: 9878117
[TBL] [Abstract][Full Text] [Related]
39. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
40. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]